Theageneio Cancer Hospital

The medical center is at the forefront of research in Multiple Myeloma, focusing on innovative maintenance therapies post-autologous stem cell transplant. The center's work aims to enhance progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM).

• Iberdomide vs. Lenalidomide Maintenance Therapy
• Advanced Monitoring Techniques in Myeloma Treatment

By exploring novel drug combinations and monitoring methods, the center is paving the way for more effective and personalized treatment strategies in multiple myeloma.

Specializing in Melanoma research, the center is dedicated to improving relapse-free survival (RFS) through advanced immunotherapy combinations. The focus is on preventing or delaying melanoma recurrence post-surgery.

• Fianlimab and Cemiplimab Combination Therapy
• Comparative Studies with Pembrolizumab

These efforts are crucial in developing superior therapeutic options that enhance patient outcomes in melanoma treatment.

The center is a leader in the study of Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer, particularly in patients previously treated with CDK4/6 inhibitors. The research focuses on progression-free survival (PFS) through innovative drug combinations.

• Gedatolisib with palbociclib and fulvestrant
• Comparative Efficacy Studies

By advancing treatment protocols, the center aims to offer more effective solutions for managing advanced breast cancer.

In the realm of Urothelial Carcinoma, the center is pioneering research to improve disease-free survival (DFS) in high-risk patients. The focus is on the efficacy of nivolumab compared to placebo.

• Nivolumab Efficacy in PD-L1 Expressing Tumors
• Placebo-Controlled Trials

This research is instrumental in refining therapeutic approaches for patients with invasive urothelial carcinoma.

The center excels in Non-Small Cell Lung Cancer research, focusing on novel therapies for both TKI-naïve and previously treated patients. The aim is to enhance progression-free survival (PFS) and overall survival (OS).

• Repotrectinib vs. Crizotinib in ROS1-positive NSCLC
• Sigvotatug Vedotin vs. Docetaxel
• Sotorasib with Chemotherapy in KRAS p.G12C Positive NSCLC

Through these studies, the center is contributing significantly to the development of targeted therapies that improve patient outcomes in NSCLC.